Is 530199 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 530199 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 530199 (₹287.05) is trading above our estimate of fair value (₹155.43)
Significantly Below Fair Value: 530199 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 530199?
Key metric: As 530199 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 530199. This is calculated by dividing 530199's market cap by their current
earnings.
What is 530199's PE Ratio?
PE Ratio
49.9x
Earnings
₹529.90m
Market Cap
₹26.41b
530199 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 530199 is expensive based on its Price-To-Earnings Ratio (49.9x) compared to the Indian Pharmaceuticals industry average (36x).
Price to Earnings Ratio vs Fair Ratio
What is 530199's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
530199 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
49.9x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 530199's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.